NCCIT Human Teratocarcinoma Cells

In 1985, Shinichi Teshima (National Cancer Institute, Tokyo, Japan) established the NCCIT cell line from a mediastinal mixed germ cell tumor. This pluripotent stem cell can differentiate into somatic cells and extraembryonic tissues. Undifferentiated cells are between seminoma and embryonal carcinoma. Differentiate under the action of retinoic acid. Keratin is negative. Vimentin and placental alkaline phosphatase were positive. The cell line was once contaminated by mycoplasma, but was cleared before being submitted to ATCC.

Animal species/Organism: Human

Tissue and Cell Type: disease of tissue origin: pluripotent embryonic carcinoma; Teratocarcinoma

Morphology: epithelial cell-like, adherent growth

Medium Formulation:

90% 1640 (MD0200)+10% fetal bovine serum (SD0200)+G/A (SD0038)

Complete medium: 1640 complete medium (MD0201)

Gas phase: air, 95%; Carbon dioxide, 5%. Temperature: 37 ℃.

Freezing conditions: basic medium+5% DMSO+20% FBS (SD0200)

Complete cryopreservation solution: No Programmed Cryopreservation Cells Solution (low Serum)(SD0001)

Declaration: This product is for scientific research only.

PubMed=2842544

Teshima S., Shimosato Y., Hirohashi S., Tome Y., Hayashi I., Kanazawa H., Kakizoe T.

Four new human germ cell tumor cell lines.

Lab. Invest. 59:328-336(1988)

PubMed=9331070

Teng D.H.-F., Perry W.L. III, Hogan J.K., Baumgard M., Bell R., Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R., Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R., Sexton D., Schroeder M., Su P.-H., Swedlund B., Kyriakis J.M., Avruch J., Bartel P., Wong A.K.C., Oliphant A., Thomas A., Skolnick M.H., Tavtigian S.V.

Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.

Cancer Res. 57:4177-4182(1997)

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31500094; DOI=10.3390/cancers11091316

Bakardjieva-Mihaylova V., Skvarova Kramarzova K., Slamova M., Svaton M., Rejlova K., Zaliova M., Dobiasova A., Fiser K., Stuchly J., Grega M., Rosova B., Zachoval R., Klezl P., Eis V., Kindlova E., Buchler T., Trka J., Boublikova L.

Molecular basis of cisplatin resistance in testicular germ cell tumors.

Cancers (Basel) 11:1316.1-1316.18(2019)